Drug Shortage Report for METHOTREXATE INJECTION USP

Last updated on 2023-07-11 History
Report ID 188454
Drug Identification Number 02182955
Brand name METHOTREXATE INJECTION USP
Common or Proper name METHOTREXATE INJECTION USP
Company Name PFIZER CANADA ULC
Market Status MARKETED
Active Ingredient(s) METHOTREXATE
Strength(s) 25MG
Dosage form(s) SOLUTION
Route of administration INTRAVENOUS INTRATHECAL INTRAMUSCULAR INTRA-ARTERIAL INTRACEREBROVENTRICULAR INTRACEREBROVENTRICULAR INTRAVENOUS INTRATHECAL INTRAMUSCULAR INTRA-ARTERIAL
Packaging size 1 x 2mL vial
ATC code L01BA
ATC description ANTIMETABOLITES
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date
Actual start date 2023-06-19
Estimated end date
Actual end date 2023-07-10
Shortage status Resolved
Updated date 2023-07-11
Company comments
Health Canada comments
Tier 3 Status No
Contact Address 17300 TRANS-CANADA HIGHWAY
KIRKLAND, QUEBEC
CANADA H9J 2M5
Company contact information Customer Service / service à la clientèle : 1-888-999-8750 Email / courriel: PharmaCustomerServiceDept@pfizer.com

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v17 2023-07-11 English Compare
v16 2023-07-10 French Compare
v15 2023-07-10 English Compare
v14 2023-06-20 English Compare
v13 2023-06-19 French Compare
v12 2023-06-19 English Compare
v11 2023-06-10 English Compare
v10 2023-05-29 French Compare
v9 2023-05-29 English Compare
v8 2023-05-27 English Compare
v7 2023-05-08 French Compare
v6 2023-05-08 English Compare
v5 2023-05-06 English Compare
v4 2023-03-31 French Compare
v3 2023-03-31 English Compare
v2 2023-03-31 French Compare
v1 2023-03-31 English Compare

Showing 1 to 17 of 17